Aligos Therapeutics Files 8-K on Security Holder Rights
Ticker: ALGS · Form: 8-K · Filed: Aug 19, 2024 · CIK: 1799448
| Field | Detail |
|---|---|
| Company | Aligos Therapeutics, Inc. (ALGS) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, bylaws
Related Tickers: ALGS
TL;DR
ALGS filed an 8-K, changes to security holder rights and bylaws, check for details.
AI Summary
Aligos Therapeutics, Inc. filed an 8-K on August 19, 2024, reporting material modifications to security holder rights and amendments to its articles of incorporation or bylaws. The filing also includes financial statements and exhibits, with the earliest event reported as August 14, 2024.
Why It Matters
This filing indicates potential changes affecting Aligos Therapeutics' security holders and corporate structure, requiring attention from investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative news.
Key Players & Entities
- Aligos Therapeutics, Inc. (company) — Registrant
- August 14, 2024 (date) — Earliest event reported
- August 19, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates material modifications to the rights of security holders, but the specific details are not elaborated in the provided text and would require reviewing the referenced exhibits.
What amendments were made to Aligos Therapeutics' articles of incorporation or bylaws?
The filing states there were amendments to the articles of incorporation or bylaws, but the exact nature of these amendments is not detailed in the provided summary and would be found in the accompanying exhibits.
What is the significance of the 'Financial Statements and Exhibits' item listed in the filing?
This item indicates that financial statements and other relevant exhibits are included with the 8-K filing, providing further details on the company's financial status and the matters discussed.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 14, 2024.
What is Aligos Therapeutics, Inc.'s primary business as indicated by its SIC code?
Aligos Therapeutics, Inc.'s Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (excluding diagnostic substances).
Filing Stats: 1,441 words · 6 min read · ~5 pages · Grade level 14.2 · Accepted 2024-08-19 16:05:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ALGS The Nasdaq
Filing Documents
- d882619d8k.htm (8-K) — 34KB
- d882619dex31.htm (EX-3.1) — 7KB
- 0001193125-24-202813.txt ( ) — 174KB
- algs-20240814.xsd (EX-101.SCH) — 3KB
- algs-20240814_lab.xml (EX-101.LAB) — 19KB
- algs-20240814_pre.xml (EX-101.PRE) — 12KB
- d882619d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to Amended and Restated Certificate of Incorporation of Aligos Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Forward-Looking Statements
Forward-Looking Statements
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALIGOS THERAPEUTICS, INC. Date: August 19, 2024 By: /s/ Lesley Ann Calhoun Lesley Ann Calhoun Executive Vice President, Chief Financial Officer